glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |
Pay in 4 interest-free payments of $6.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://content.abcam.com/products/images/glp-1-antibody-epr4042-407-ab111125--multiplex-immunohistochemistry-img460297.jpg)
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsrep26236/MediaObjects/41598_2016_Article_BFsrep26236_Fig3_HTML.jpg)
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://content.abcam.com/products/images/glp-1-antibody-epr4042-1-ab108443--immunohistochemistry-formalin-pfa-fixed-paraffin-embedded-sections-img439821.jpg)
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://content.abcam.com/products/images/glp-1r-antibody-epr21819-ab218532--immunohistochemistry-frozen-sections-img34413.jpg)
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://www.researchgate.net/publication/377981370/figure/fig1/AS:11431281291619608@1732162478824/Conjugation-of-GLP-1-peptide-analog-to-GIPR-antibody-AMG-133-chemical-structure.jpg)
![glp-1 antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites ICC/IF and reacts with Human samples Anti-GLP-1 antibody [EPR4042-407] (ab111125) |](https://www.researchgate.net/publication/329348144/figure/fig2/AS:776893259337733@1562237195644/Stability-engineering-of-GLP-1-analogue-peptides-in-fusion-with-anti-PCSK9-Ab2-Human-Fc.jpg)











.jpg)








